Reference #: 3005115135 Product: Drugs Recipient: Recipient Name Mr. V.N. Gopalkrishnan Recipient Title Co-Founder & Chairman Malladi Drugs & Pharmaceuticals Ltd. SKCL Tech Square, 7th Floor, […]

Summary Company Announcement Date: February 02, 2023 FDA Publish Date: February 02, 2023 Product Type: Drugs Reason for Announcement: Recall Reason Description Potential microbial contamination Company […]

The FY 2022 GDUFA science and research report describes active research projects and outcomes organized in 13 scientific areas. In each area, we summarize the relevant […]

[2-2-2023] The Food and Drug Administration is advising consumers not to purchase or use MANNERS Energy Boost, a product promoted and sold to boost energy on […]

By: Marta Sokolowska, Ph.D., CDER Deputy Center Director for Substance Use and Behavioral Health Marta Sokolowska, Ph.D. The overdose crisis is one of the most devastating […]

For Immediate Release: February 01, 2023 Today, the U.S. Food and Drug Administration approved Jesduvroq tablets (daprodustat) as the first oral treatment for anemia (decreased number […]

Summary Company Announcement Date: January 31, 2023 FDA Publish Date: February 01, 2023 Product Type: Drugs Reason for Announcement: Recall Reason Description Subpotency Company Name: IBSA […]

Submit Comments by 04/01/2023 Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment […]

[20/01/2023] En un esfuerzo por mejorar el suministro de ibuprofeno preparado en suspensión oral en medio de una demanda récord, la FDA está publicando una guía […]